|
1
|
Zuo TT, Zheng RS, Zhang SW, Zeng HM and
Chen WQ: Incidence and mortality of liver cancer in China in 2011.
Chin J Cancer. 34:508–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryerson AB, Eheman CR, Altekruse SF, Ward
JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM,
et al: Annual report to the nation on the status of cancer,
1975–2012, featuring the increasing incidence of liver cancer.
Cancer. 122:1312–1337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Utsunomiya T, Shimada M, Imura S, Morine
Y, Ikemoto T and Mori M: Molecular signatures of noncancerous liver
tissue can predict the risk for late recurrence of hepatocellular
carcinoma. J Gastroenterol. 45:146–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jain RK: Normalizing tumor
microenvironment to treat cancer: Bench to bedside to biomarkers. J
Clin Oncol. 31:2205–2218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Paradis V, Kudo M and
Zucman-Rossi J: Tissue biomarkers as predictors of outcome and
selection of transplant candidates with hepatocellular carcinoma.
Liver Transpl. 17 Suppl 2:S67–S71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu LC, Hsu CH, Hsu C and Cheng AL: Tumor
heterogeneity in hepatocellular carcinoma: Facing the challenges.
Liver Cancer. 5:128–138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao Q, Wang ZC, Duan M, Lin YH, Zhou XY,
Worthley DL, Wang XY, Niu G, Xia Y, Deng M, et al: Cell culture
system for analysis of genetic heterogeneity within hepatocellular
carcinomas and response to pharmacologic agents. Gastroenterology.
152:232–242. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xue R, Li R, Guo H, Guo L, Su Z, Ni X, Qi
L, Zhang T, Li Q, Zhang Z, et al: Variable intra-tumor genomic
heterogeneity of multiple lesions in patients with hepatocellular
carcinoma. Gastroenterology. 150:998–1008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Essien BE, Sundaresan S, Ocadiz-Ruiz R,
Chavis A, Tsao AC, Tessier AJ, Hayes MM, Photenhauer A,
Saqui-Salces M, Kang AJ, et al: Transcription factor ZBP-89 drives
a feedforward loop of β-catenin expression in colorectal cancer.
Cancer Res. 76:6877–6887. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borghaei RC, Gorski G, Seutter S, Chun J,
Khaselov N and Scianni S: Zinc-binding protein-89 (ZBP-89)
cooperates with NF-kB to regulate expression of matrix
metalloproteinases (MMPs) in response to inflammatory cytokines.
Biochem Biophys Res Commun. 471:503–509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye CG, Chen GG, Ho RLK, Merchant JL, He ML
and Lai PBS: Epigenetic upregulation of Bak by ZBP-89 inhibits the
growth of hepatocellular carcinoma. Biochim Biophys Acta.
1833:2970–2979. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leupold JH, Asangani IA, Mudduluru G and
Allgayer H: Promoter cloning and characterization of the human
programmed cell death protein 4 (pdcd4) gene: Evidence for ZBP-89
and Sp-binding motifs as essential Pdcd4 regulators. Biosci Rep.
32:281–297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bai L and Merchant JL: Transcription
factor ZBP-89 is required for STAT1 constitutive expression.
Nucleic Acids Res. 31:7264–7270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bai L and Merchant JL: Transcription
factor ZBP-89 cooperates with histone acetyltransferase p300 during
butyrate activation of p21waf1 transcription in human cells. J Biol
Chem. 275:30725–30733. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng Y, Wang X, Xu L, Pan H, Zhu S, Liang
Q, Huang B and Lu J: The transcription factor ZBP-89 suppresses p16
expression through a histone modification mechanism to affect cell
senescence. FEBS J. 276:4197–4206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Y, Zhang X, Salmon M and Zehner ZE: The
zinc finger repressor, ZBP-89, recruitshistone deacetylase 1 to
repress vimentin gene expression. Genes Cells. 12:905–918. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Diab IH and Zehner ZE: ZBP-89
represses vimentin gene transcription by interacting with the
transcriptional activator, Sp1. Nucleic Acids Res. 31:2900–2914.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Remington MC, Tarle SA, Simon B and
Merchant JL: ZBP-89, a Kruppel-type zinc finger protein, inhibits
cell proliferation. Biochem Biophys Res Commun. 237:230–234. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Merchant JL, Iyer GR, Taylor BR, Kitchen
JR, Mortensen ER, Wang Z, Flintoft RJ, Michel JB and Bassel-Duby R:
ZBP-89, a Kruppel-like zinc finger protein, inhibits epidermal
growth factor induction of the gastrin promoter. Mol Cell Biol.
16:6644–6653. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang CZ, Cao Y, Yun JP, Chen GG and Lai
PB: Increased expression of ZBP-89 and its prognostic significance
in hepatocellular carcinoma. Histopathology. 60:1114–1124. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taniuchi T, Mortensen ER, Ferguson A,
Greenson J and Merchant JL: Overexpression of ZBP-89, a zinc finger
DNA binding protein, in gastric cancer. Biochem Biophys Res Commun.
233:154–160. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan SM, Wu HN, He F, Hu XP, Zhang ZY,
Huang MY, Wu X, Huang CY and Li Y: High expression of zinc-binding
protein-89 predicts decreased survival in esophageal squamous cell
cancer. Ann Thorac Surg. 97:1966–1973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nilton A, Sayin VI, Zou ZV, Sayin SI,
Bondjers C, Gul N, Agren P, Fogelstrand P, Nilsson O, Bergo MO and
Lindahl P: Targeting Zfp148 activates p53 and reduces tumor
initiation in the gut. Oncotarget. 7:56183–56192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cai MY, Luo RZ, Li YH, Dong P, Zhang ZL,
Zhou FJ, Chen JW, Yun JP, Zhang CZ and Cao Y: High-expression of
ZBP-89 correlates with distal metastasis and poor prognosis of
patients in clear cell renal cell carcinoma. Biochem Biophys Res
Commun. 426:636–642. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bai L, Logsdon C and Merchant JL:
Regulation of epithelial cell growth by ZBP-89: Potential relevance
in pancreatic cancer. Int J Gastrointest Cancer. 31:79–88. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Altman DG, McShane LM, Sauerbrei W and
Taube SE: Reporting recommendations for tumor marker prognostic
studies (REMARK): Explanation and elaboration. PLoS Med.
9:e10012162012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moons KG, Altman DG, Reitsma JB and
Collins GS: Transparent Reporting of a Multivariate Prediction
Model for Individual Prognosis or Development Initiative: New
guideline for the reporting of studies developing, validating, or
updating a multivariable clinical prediction model: The TRIPOD
statement. Adv Anat Pathol. 22:303–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pirisi M, Leutner M, Pinato DJ, Avellini
C, Carsana L, Toniutto P, Fabris C and Boldorini R: Reliability and
reproducibility of the edmondson grading of hepatocellular
carcinoma using paired core biopsy and surgical resection
specimens. Arch Pathol Lab Med. 134:1818–1822. 2010.PubMed/NCBI
|
|
29
|
Mohamadnejad M, Tavangar SM, Sotoudeh M,
Kosari F, Khosravi M, Geramizadeh B, Montazeri G, Estakhri A,
Mirnasseri MM, Fazlollahi A, et al: Histopathological study of
chronic hepatitis B: A comparative study of ishak and METAVIR
scoring systems. Int J Organ Transplant Med. 1:171–176.
2010.PubMed/NCBI
|
|
30
|
Chan JK: The wonderful colors of the
hematoxylin-eosin stain in diagnostic surgical pathology. Int J
Surg Pathol. 22:12–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang CZ, Chen GG and Lai PB:
Transcription factor ZBP-89 in cancer growth and apoptosis. Biochim
Biophys Acta. 1806:36–41. 2010.PubMed/NCBI
|
|
32
|
Gao XH, Liu QZ, Chang W, Xu XD, Du Y, Han
Y, Liu Y, Yu ZQ, Zuo ZG, Xing JJ, et al: Expression of ZNF148 in
different developing stages of colorectal cancer and its prognostic
value: A large Chinese study based on tissue microarray. Cancer.
119:2212–2222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bai L and Merchant JL: ZBP-89 promotes
growth arrest through stabilization of p53. Mol Cell Biol.
21:4670–4683. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okada M, Tessier A, Bai L and Merchant JL:
P53 mutants suppress ZBP-89 function. Anticancer Res. 26:2023–2028.
2006.PubMed/NCBI
|
|
35
|
Fang J, Jia J, Makowski M, Xu M, Wang Z,
Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, et al: Functional
characterization of a multi-cancer risk locus on chr5p15.33 reveals
regulation of TERT by ZNF148. Nat Commun. 8:150342017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiang T, Zhang S, Cheng N, Ge S, Wen J,
Xiao J and Wu X: Oxidored-nitro domain-containing protein 1
promotes liver fibrosis by activating the Wnt/β-catenin signaling
pathway in vitro. Mol Med Rep. 16:5050–5054. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miao CG, Yang YY, He X, Huang C, Huang Y,
Zhang L, Lv XW, Jin Y and Li J: Wnt signaling in liver fibrosis:
Progress, challenges and potential directions. Biochimie.
95:2326–2335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng JH, She H, Han YP, Wang J, Xiong S,
Asahina K and Tsukamoto H: Wnt antagonism inhibits hepatic stellate
cell activation and liver fibrosis. Am J Physiol Gastrointest Liver
Physiol. 294:G39–G49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Whittaker S, Marais R and Zhu AX: The role
of signaling pathways in the development and treatment of
hepatocellular carcinoma. Oncogene. 29:4989–5005. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo Y, Xiao L, Sun L and Liu F:
Wnt/beta-catenin signaling: A promising new target for fibrosis
diseases. Physiol Res. 61:337–346.. 2012.PubMed/NCBI
|
